Phase II study of arsenic trioxide in patients with multiple myeloma

Trial Profile

Phase II study of arsenic trioxide in patients with multiple myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2014

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 30 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top